Interviewed during DCAT Week 2024, Stephen Houldsworth, Senior VP, Global Head of Platform Management & Marketing at Corden Pharma, speaks about the highlights of Small Molecule technology platform including capex investments in our Bergamo (IT) site with an additional 45,000 L of reactor capacity, expansion in the Chenôve (FR) facility with new 6,000 L reactors, and additional capacity in the Solid-State group in Liestal (CH) with polymorphic form analysis for APIs.
On the Small Molecule Drug Product side, a new oral liquid line in the Fribourg (CH) site, and a significant capacity increase in the Lisbon (PT) facility for capsule and tablet manufacturing and granulation techniques.